Patents Assigned to Western Sydney Local Health District
  • Patent number: 11951127
    Abstract: The present disclosure relates to compositions comprising isolated T cells, with activity against a fungal antigen, a viral antigen or a tumour antigen, wherein the composition comprises a defined number or defined ratio of T cells. Described herein are compositions comprising at least two populations of T cells, the compositions being suitable for treating various diseases and disorders.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: April 9, 2024
    Assignees: THE WESTMEAD INSTITUTE FOR MEDICAL RESEARCH, THE UNIVERSITY OF SYDNEY, WESTERN SYDNEY LOCAL HEALTH DISTRICT, NEW SOUTH WALES HEALTH PATHOLOGY
    Inventors: Emily Blyth, Leighton Clancy, David Gottlieb, Kenneth Micklethwaite
  • Patent number: 11674181
    Abstract: A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstitial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: June 13, 2023
    Assignees: Icahn School of Medicine at Mount Sinai, Western Sydney Local Health District
    Inventors: Barbara Murphy, Weijia Zhang, Philip J. O'Connell
  • Patent number: 11517264
    Abstract: A method of monitoring cardiac dysfunction, such as pericardial effusion, is disclosed. The method uses an indwelling probe inserted within a coronary sinus or a chamber or vessel of the heart, the probe having motion sensing means configured to sense motion of the probe based on movement of the wall of the coronary sinus or other chamber or vessel. Data is obtained from the motion sensing means and processed to monitor for cardiac dysfunction. The monitoring can be in real-time and can utilise one or more three-axis accelerometers. In some embodiments, two or more three-axis accelerometers are spaced longitudinally along an elongate body of the probe, which can increase accuracy and reliability of monitoring.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: December 6, 2022
    Assignee: Western Sydney Local Health District
    Inventors: Pramesh Kovoor, Jim Pouliopoulos, Tony Barry
  • Publication number: 20210401495
    Abstract: A system for monitoring tissue lesion development during a medical ablation process applied to a patient, the system comprising a catheter ablation device having at least one catheter electrode, the device connectable via an electrical feedline to a source of electrical energy and configured to apply ablation energy to ablate tissue in a target region, a plurality of external electrodes for application to the body of the patient, measurement circuitry for determining an electrical characteristic of a current path between the at least one catheter electrode and the external electrodes in the absence of said application of ablation energy, and an electrical controller.
    Type: Application
    Filed: September 7, 2021
    Publication date: December 30, 2021
    Applicants: The University of Sydney, Western Sydney Local Health District
    Inventors: Pierre Qian, Michael Anthony Barry, Alistair McEwan, Duc Minh Nguyen
  • Publication number: 20210196378
    Abstract: The invention relates to a catheter ablation device for delivery of energy to a selected region of tissue, the device having an antenna portion including a radiating antenna electrically connectable via an electrical feedline to a source of energy, the antenna configured to generate an electromagnetic field able to ablate tissue in said selected region of tissue, the device including a thermocouple having a hot junction formed by electrical connection between a thermocouple conductor and a conducting part of the electrical feedline. This avoids the need for a dedicated thermocouple conductor pair, as the second conductor of the thermocouple is provided by the feedline used to supply the ablation energy to the device antenna.
    Type: Application
    Filed: February 9, 2021
    Publication date: July 1, 2021
    Applicants: The University of Sydney, Western Sydney Local Health District
    Inventors: Pierre Qian, Michael Anthony Barry
  • Publication number: 20210186609
    Abstract: The invention relates to a catheter ablation device for delivery of energy (such as microwave energy) via a radiating antenna to a selected region of tissue, the device having an elongated catheter with an outer sheath, configured to allow flow of fluid along the catheter to exit through one or more orifices adjacent to the antenna. The device includes an impedance monitoring system having two electrodes arranged respectively inside and outside said catheter sheath, the impedance monitoring system including an electric circuit incorporating an ionic conductivity path through said fluid. The device is introduced into a blood vessel and the invention allows monitoring of changes in the size of the blood vessel during an ablation procedure, as it can be used to measure the impedance of an electrical circuit including a blood path in the blood vessel in the region of the ablation, the measured impedance providing a measure of vascular calibre.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 24, 2021
    Applicants: The University of Sydney, Western Sydney Local Health District
    Inventors: Pierre Qian, Michael Anthony Barry
  • Publication number: 20210186608
    Abstract: The invention relates to an ablation device for delivery of microwave energy to a selected region of tissue, in particular for producing deep endocardial or epicardial ventricular lesions, such as for the treatment or prevention of arrhythmias.
    Type: Application
    Filed: January 6, 2021
    Publication date: June 24, 2021
    Applicants: The University of Sydney, Western Sydney Local Health District
    Inventors: Pierre Qian, Michael Anthony Barry
  • Patent number: 11039884
    Abstract: A microwave ablation device (10) comprises a feed line (22), a microwave radiator and a device outer sheath (46) in which at least part of the feed line (22) is contained. The sheath (46) in use, allows an irrigation liquid to flow therethrough, wherein the feed line has a junction (38) with the radiator (22) has an outer conducting shield (28) terminating and insulated at the junction (38). The feed line (22) has a conductive core (32) that extends to the radiator (24). The conductive core forms a radiating element (34) electrically insulated from its surrounding environment. The radiator (24) is unbalanced.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: June 22, 2021
    Assignees: The University of Sydney, Western Sydney Local Health District
    Inventors: Pierre Qian, Michael Anthony Barry
  • Patent number: 10941446
    Abstract: A method for identifying a renal allograft recipient at risk for chronic allograft damage or interstutial fibrosis and tubular atrophy (IF/TA) by comparing the transcription level of a preselected gene signature set with the transcription level of a comparison standard, and diagnosing the recipient as being at risk for chronic allograft damage if the transcription level of the preselected gene signature set is significantly higher than the transcription level of the comparison standard.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: March 9, 2021
    Assignees: Icahn School of Medicine at Mount Sinai, Western Sydney Local Health District
    Inventors: Barbara Murphy, Weijia Zhang, Philip J. J. O'Connell
  • Patent number: 10940165
    Abstract: The present disclosure provides a composition comprising isolated T cells, wherein the T cells have specificity against a range of clinical fungal pathogens.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: March 9, 2021
    Assignees: The University of Sydney, Western Sydney Local Health District, Westmead Institute for Medical Research, NSW Health Pathology
    Inventors: David Gottlieb, Leighton Clancy, Emily Blyth, Kenneth Paul Micklethwaite, Shivashni Deo
  • Patent number: 10939868
    Abstract: This invention relates to molecular diagnostics and, more specifically DNA-based tests for the prognosis and/or monitoring of fibrotic disease progression in humans, and processes for stratifying patients based on their likely rates of fibrotic disease progression. The invention also relates to the field of therapy for fibrotic disease, based on such prognoses, monitoring and stratification results, such as in monitoring and/or stratifying and/or treating patients having a higher likelihood of rapid fibrotic disease progression.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: March 9, 2021
    Assignees: WESTERN SYDNEY LOCAL HEALTH DISTRICT, THE UNIVERSITY OF SYDNEY
    Inventors: David Booth, Jacob George, Mohammed Eslam, Golo Ahlenstiel, Kate O'Connor
  • Publication number: 20200375658
    Abstract: The invention concerns a method for intra-operative monitoring of the effectiveness of transcatheter renal denervation in a patient, to assist in guiding the procedure and in particular for identifying a physiological procedural endpoint. Through aorticorenal ganglia pace-capture, renal sympathetic nerve function can be assessed. In accordance with the invention, sustained reduction or abolition of renal vasoconstriction induced by the pacing is used as an indicator of successful renal denervation.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 3, 2020
    Applicants: The University of Sydney, Western Sydney Local Health District
    Inventors: Pierre Qian, Michael Anthony Barry
  • Patent number: 10722178
    Abstract: A method for the reduction of motion artifacts in CT imaging, the method including the steps of: (a) reconstructing from the raw CT data an initial estimate of the object of interest; (b) estimating the pose of the object at each projection angle; (c) undertaking a motion-corrected reconstruction from the measured projections, accounting for the pose changes estimated in (b) by employing a modified source/detector orbit that accounts for the object motion; (d) iterating steps (b)-(c) until a predetermined convergence criterion is met; and (e) making a final reconstruction of the required image size using the pose estimates obtained in the previous steps.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 28, 2020
    Assignees: Western Sydney Local Health District, The University of Sydney, Katholieke Universiteit Leuven KU Leuven R&D
    Inventors: Roger Fulton, Johan Nuyts, Tao Sun, Jung-Ha Kim
  • Patent number: 10725026
    Abstract: A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: July 28, 2020
    Assignees: Icahn School of Medicine at Mount Sinai, Westmead Institute For Medical Research, Western Sydney Local Health District
    Inventors: Barbara Murphy, Philip J. O'Connell
  • Publication number: 20190070220
    Abstract: The present disclosure provides a composition comprising isolated T cells, wherein the T cells have specificity against a range of clinical fungal pathogens.
    Type: Application
    Filed: July 7, 2016
    Publication date: March 7, 2019
    Applicants: The University of Sydney, Western Sydney Local Health District
    Inventors: David Gottlieb, Leighton Clancy
  • Publication number: 20180221089
    Abstract: A microwave ablation device (10) comprises a feed line (22), a microwave radiator and a device outer sheath (46) in which at least part of the feed line (22) is contained. The sheath (46) in use, allows an irrigation liquid to flow therethrough, wherein the feed line has a junction (38) with the radiator (22) has an outer conducting shield (28) terminating and insulated at the junction (38). The feed line (22) has a conductive core (32) that extends to the radiator (24). The conductive core forms a radiating element (34) electrically insulated from its surrounding environment. The radiator (24) is unbalanced.
    Type: Application
    Filed: June 10, 2016
    Publication date: August 9, 2018
    Applicants: The University of Sydney, Western Sydney Local Health District
    Inventors: Pierre Qian, Michael Anthony Barry
  • Patent number: 9816985
    Abstract: A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: November 14, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, Westmead Institure For Medical Research, Western Sydney Local Health District
    Inventors: Barbara Murphy, Philip J. O'Connell
  • Patent number: 8673869
    Abstract: The present invention provides methods for determining the level of resistance of a tumor cell to one or more chemotherapeutic agents, comprising measuring the level of expression of a muscle ankyrin repeat protein in the tumor cell. The invention also provides methods for increasing the sensitivity of a tumor cell to one or more chemotherapeutic agents, comprising administering to the cell an effective amount of an antagonist of a muscle ankyrin repeat protein. The invention further provides compositions for use in accordance with methods of the invention.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: March 18, 2014
    Assignee: Western Sydney Local Health District
    Inventors: Anna De Fazio, Paul Robert Harnett, Alexander David Guminski